Castaneda D,Gonzalez AJ,Alomari M,Tandon K,Zervos XB .2021 .From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol, 27 : 1691-1715.
Hepatitis C . .[cited 2023 Feb6]. , : .
Razavi H,Sanchez Gonzalez Y,Yuen C,Cornberg M. .2019 .Global timing of hepatitis C virus elimination in high‐income countries. Liver Int, 40 : 522-9.
Alosaimi K,Alwafi H,Alhindi Y,Falemban A,Alshanberi A,Ayoub N .2022 .Medication adherence among patients with chronic diseases in Saudi Arabia. Int J Environ Res Public Health, 19 : 10053.
Mravcik V,Strada L,Stolfa J,Bencko V,Groshkova T,Reimer J .2013 .Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence, 7 : 1067-75.
Coco LT,Silva GF,Romeiro FG,Cerqueira AT .2022 .Factors associated with hepatitis C treatment adherence: an integrative review. Cienc Saude Coletiva, 27 : 1359-76.
World Hepatitis Day 2021: Hepatitis Can't Wait . .. , : .
. .-2021-hepatitis-cant-wait. World Health Organization. World Health Organization; [cited 2023 Jan, 25 : .
Mahmud S,Abu-Raddad Z,LJ Z .2019 .Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis, 19 : 1-1.
Schwambach KH,Farias MR,Neto GB,Blatt CR .2020 .Cost, and effectiveness of the treatment of chronic hepatitis C in Brazil: Real-World Data. Value Health Reg Issues, 23 : 49-54.
Kind J,Maeschli B,Bruggmann P .2022 .How to set the agenda for hepatitis C: A theory-driven policy analysis. Health. Res Policy Syst, 20 : 20.
Malespin M,Harris C,Kanar O,Jackman K,Smotherman C,Johnston A .2019 .Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic. Ann Hepatol, 18 : 304-9.
Ahmed MM,O. Shaarawy H,Anwar I,Sarhan MD .2021 .Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt. J Prim Care Community Health, 12 : 1-6.
Morisky DE,Ang A,Krousel‐Wood M,Ward HJ .2008 .Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens, 10 : 348-54.
Clark PJ,Valery PC,Strasser SI,Weltman M,Thompson AJ,Levy M .2022 .Liver disease and poor adherence limit hepatitis C cure: a real-world Australian treatment cohort. Dig Dis Sci, 68 : 291-303.
Serper M,Evon DM,Stewart PW,Lok AS,Amador J,Reeve BB .2019 .Medication non-adherence in a prospective, multi-center cohort treated with hepatitis C direct-acting antivirals. J Gen Intern Med, 35 : 1011-20.
Ivantes CA,Silva BC,Acosta GG,Tawil FB,Nisihara R .2021 .Non-adherence to hepatitis C treatment: a Brazilian report. Arquivos de Gastroenterologia, 58 : 456-60.
Cooper CL,Galanakis C,Donelle J,Kwong J,Boyd R,Boucher L .2019 .HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis, 19 : 1-5.
Aleman S,Soderholm J,Busch K,Kovamees J,Duberg AS .2020 .Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus. Liver Int, 40 : 1832-40.
Pericot-Valverde I,Heo M,Akiyama MJ,Norton BL,Agyemang L,Niu J .2020 .Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: Secondary analysis of the prevail randomized clinical trial. BMC Infect Dis, 20 : 1-11.
Philip TJ,Crosby KM,Frank-Pearce SG,Wendelboe AM,Solberg M,Weakley J .2022 .Factors impacting medication adherence in a birth cohort at higher risk for Hepatitis C infection. Baltimore Md, 101 : e32354.